Cure Pharmaceutical logo

Cure Pharmaceutical(OTC) CURR

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-100%
1 Year+0%
1 Month+19,900%
N/A
Cure Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-12
Cure Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-10-05
1 month+19,900%USD 0.002026-09-11
3 month+19,900%USD 0.002026-07-14
Year to date-50%USD 0.002025-12-31
1 year+0%USD 0.002025-10-09
3 year-99.75%USD 0.082023-10-13
5 year-99.97%USD 0.592021-10-13
Since inception-99.99%USD 2.052017-01-19

Cure Pharmaceutical Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$37.81M

Net Income (TTM)

-$18.43M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 27, 2026

CURR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cure Pharmaceutical

Currenc Group, Inc. operates a financial technology banking platform, focusing on remittance services and airtime sales. The company is headquartered in Singapore and aims to provide diverse financial solutions to its customers.

Products and Services
  • Remittance services for international money transfers
  • Airtime sales for mobile phone top-ups
  • Diverse financial technology solutions tailored for users
Growth Outlook
  • Revenue increased to $10.39 million in Q3 2025, showing strong demand
  • Gross profit margin improved to 50.76% in Q3 2025, indicating operational efficiency
  • Cash and cash equivalents reached $75.24 million in Q4 2025, providing liquidity
Financial Highlights
  • Net income for Q4 2025 was -$12.01 million, reflecting ongoing challenges
  • Operating income ratio was -46.55% in Q4 2025, highlighting cost management issues
  • Cash flow from operations was $20.27 million in Q4 2025, demonstrating cash generation
Currenc Group, Inc. is positioned in the financial technology sector, focusing on innovative solutions for remittance and airtime services. The company has shown promising revenue growth, particularly in the third quarter of 2025, with a notable increase in gross profit margin. However, challenges remain, as evidenced by the negative net income and operating income ratios in the most recent quarter. The substantial cash reserves indicate a strong liquidity position, which may support future growth initiatives. Investors may find the company's trajectory and market potential worth monitoring as it navigates its operational challenges.
AI Generated • Oct 1, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

11

CEO

Nancy Duitch

Website

www.avenirwellness.com

Headquarters

Singapore, CE 188726, SG

CURR Financials

Key Financial Metrics (TTM)

Gross Margin

44.01%

Operating Margin

-13.03%

Net Income Margin

-49.56%

Return on Equity

66.19%

Return on Capital

-70.19%

Return on Assets

-12.06%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$15.42M

Operating Income

-$7.94M

EBITDA

-$11.36M

Operating Cash Flow

$7.86M

Capital Expenditure

-$479.04K

Free Cash Flow

$7.38M

Cash & ST Invst.

$78.64M

Total Debt

$16.97M

Cure Pharmaceutical Performance Analysis

Cure Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 6,078,000N/A
20222022-12-31USD 4,896,000-19.4%
20232023-12-31USD 4,347,000-11.2%
Cure Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-9.1%
Q22025-06-30-13.4%
Q32025-09-3019.3%
Q42025-12-31-16.8%
Cure Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.14N/A
20222022-12-31USD -0.2691.9%
20232023-12-31USD -0.05-81.9%
Cure Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3181.9%
Q22025-06-3023.1%
Q32025-09-30151.6%
Q42025-12-31-410.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$8.65M

-21.8%

Gross Profit

$3.70M

+13.7%

Gross Margin

42.74%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

293

N/A

Net Income

-$12.01M

+56.6%

EBITDA

-$10.47M

+60.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$78.64M

+23.2%

Total Debt

$16.97M

-24.5%

Accounts Receivable

$19.49M

-4.4%

Inventory

$601.95K

+2.4%

Long Term Debt

$4.60M

+2836.2%

Short Term Debt

$12.37M

-44.6%

Return on Assets

-12.06%

N/A

Return on Invested Capital

-15.19%

N/A

Free Cash Flow

$19.79M

+36.1%

Operating Cash Flow

$20.27M

+34.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CPSSConsumer Portfolio Services, Inc.
$9.07-0.98%
LPROOpen Lending Corporation
$3.14+0.00%
PMTSCPI Card Group Inc.
$25.31-1.56%
STEXStreamex Corp.
$0.43-5.99%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$221.30-3.16%
BACBank of America
$51.39-4.76%
CRWVCoreWeave
$65.78-15.46%
INTCIntel
$98.12-4.56%

Questions About CURR

What is the current price of Cure Pharmaceutical?

Cure Pharmaceutical is trading at N/A per share.

What is the 52-week range for Cure Pharmaceutical?

Over the past 52 weeks, Cure Pharmaceutical has traded between N/A and N/A.

How much debt does Cure Pharmaceutical have?

As of the most recent reporting period, Cure Pharmaceutical reported total debt of $8.28M.

How much cash does Cure Pharmaceutical have on hand?

Cure Pharmaceutical reported $49.00K in cash and cash equivalents in its most recent financial results.

What is Cure Pharmaceutical’s dividend yield?

Cure Pharmaceutical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services